WHO naming stem · suffix · 32 listed names
-dotin
This page was written with AI.
synthetic derivatives of dolastatin series
Where it sits in a name
WHO writes the stem as -dotin. So the letters dotin sit at the end of the name (…dotin).
All 32 names WHO lists under -dotin
These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.
Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 6 of 32 names appear in these lists: 6 in the US list (FDA Drugs@FDA) and 5 in the EU central list (EMA); 5 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.
- anvatabart opadotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- aprutumab ixadotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- azintuxizumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- belantamab mafodotinUS brands: BLENREPEU (central) brands: Blenrep
- brentuximab vedotinUS brands: ADCETRISEU (central) brands: Adcetris
- cemadotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- cofetuzumab pelidotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- denintuzumab mafodotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- depatuxizumab mafodotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- enapotamab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- enfortumab vedotinUS brands: PADCEVEU (central) brands: Padcev
- glembatumumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- iladatuzumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- indusatumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- ladiratuzumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- lifastuzumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- lonigutamab ugodotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- losatuxizumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- pinatuzumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- polatuzumab vedotinUS brands: POLIVYEU (central) brands: Polivy
- samrotamab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- sirtratumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- soblidotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- sofituzumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- tasidotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- telisotuzumab vedotinUS brands: EMRELISEU (central) brands: none found
- tisotumab vedotinUS brands: TIVDAKEU (central) brands: Tivdak
- trastuzumab botidotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- upinetatug rilsodotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- vandortuzumab vedotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- vorsetuzumab mafodotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
- zanidatamab zovodotinNot found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.
EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.
EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.
Decode another name
Decoded
cemadotin
Listed INNCarries the WHO stem -dotin
- -dotinend of the nameWHO lists it hereWHO definition: synthetic derivatives of dolastatin series
“cemadotin” is an INN that WHO lists under -dotin in the 2024 stem book.
The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.
Source and licence
The definition of -dotin (Part II B) and the 32 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .
Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.